Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC Who Progressed on CDK4/6 Inhibitors By Ogkologos - September 23, 2025 387 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ICARUS-BREAST01 study Source RELATED ARTICLESMORE FROM AUTHOR Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... MOST POPULAR Pink Speed Bump Reminds Drivers to Schedule Their Yearly Mammograms November 1, 2019 Are New Immune-Based Treatments for Kidney and Pancreatic Cancer on the... April 23, 2025 FDA Approves Cemiplimab-rwlc in Combination with Platinum-Based Chemotherapy for Advanced NSCLC November 25, 2022 How to Prepare for Lung Cancer Treatment to Help With Recovery December 15, 2022 Load more HOT NEWS Developing Biomarkers for Immunotherapy: A Conversation with Drs. Magdalena Thurin and... Front-line Anti-PD1 Treatment Outperforms BRAF/MEK Therapy in BRAFV600-mutant Advanced Melanoma Promising Cancer Drug Combines Chemo And Light Therapy Into One Powerful... Adding Tafasitamab and Lenalidomide to R-CHOP Improves PFS in Patients with...
